🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Byju’s, Pharmeasy 'large underperformers' in Prosus’ India H1 FY24 portfolio

Published 30-11-2023, 12:49 am
Byju’s, Pharmeasy 'large underperformers' in Prosus’ India H1 FY24 portfolio

New Delhi, Nov 29 (IANS) Investment firm Prosus has identified edtech firm Byju’s and health-tech company Pharmaeasy among the “large underperformers” in its first half of FY24 India portfolio.According to the company's half-yearly financials report, while Byju's had a negative internal rate of return (IRR) of 24 per cent, Pharmaeasy had a negative IRR of 41 per cent in H1 FY24, reports Moneycontol.

Prosus has also marked down the value of its stake in Byju’s to less than $3 billion, representing a decline of more than 86 per cent from the previous funding round valuation of $22 billion.

Since 2018, Prosus has invested $536 million in Byju's. It revalued the investment to $493 million in June, an 8 per cent decrease. In addition to Prosus, Byju's early sponsor Blackrock (NYSE:BLK) has reduced its interest in the company.

In November last year, Prosus first slashed the fair value of Byju's to $5.97 billion.

"Byju's is more challenged and the company is facing multiple headwinds. We and other shareholders are working everyday to improve the situation. We are in close discussions with the company every day," a senior Prosus executive said.

While debt investors sued the edtech firm after it missed payment deadlines, Peak XV (formerly Sequoia), Prosus, and Chan Zuckerberg resigned from Byju's board after the company failed to submit its audited financial records for FY22 and FY23.

Prosus has also slashed Pharmeasy's valuation down to half from $5.6 billion, while the company is attempting to raise a new round at a lower valuation of up to 90 per cent, the report mentioned.

"Another is a write down in Pharmeasy of about $118 million and that's really driven by the need for Pharmeasy to raise money to settle debt. We actually participated in that round which expresses our confidence in the business going forward," a Prosus spokesperson was quoted as saying.

Meanwhile, Prosus gained profits from other Indian companies in its portfolio, such as Swiggy, Eruditus, PayU India, Meesho, and Elastic Run.

Swiggy generated a 7 per cent IRR for Prosus, while Eruditus generated a 22 per cent IRR. In the first of FY24, it also achieved 30 per cent positive returns from PayU India, 32 per cent from Meesho, and 31 per cent from Elastic Run.


Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.